Page 503 - Clinical Hematology_ Theory _ Procedures ( PDFDrive )

CHAPTER 24 ■ Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms 487

REVIEW QUESTIONS (continued)

*9. An ppropri te escription o re r ctory ne i (RA) is *11. An ppropri te escription o re r ctory ne i with

A. ne i , no bl st excess bl sts, type 1 RAEB

B. ne i , less th n 1% bl sts A. ne i , no bl sts

C. cytopeni , less th n 5% bl sts, no Auer ro s B. ne i , less th n 1% bl sts

C. cytopeni , less th n 5% bl sts, no Auer ro s

*10. An ppropri te escription o re r ctory ne i with

ring si erobl ts (RARS) is *12. In young p tients, the ther py o choice or MDSs

A. ne i , no bl sts involves

B. ne i , less th n 1% bl sts A. vit ins

C. cytopeni , less th n 5% bl sts, no Auer ro s B. llogeneic bone rrow tr nspl nt tion

C. cytotoxic rugs

D. colony-sti ul ting growth ctors

Leone G. T er py-rel te leuke i n yelo yspl si : susceptibility
COMPANION RES OURCES n inci ence, Hemotologica, 92(10):1389–1398, 2007.

List A, Kurtin S, Roe DJ, et l. E c cy o len li o i e in the yelo ys-
http://thepoint.lww.co / urgeon6e
pl stic syn ro es, N Eng J Med, 352(6):549–557, 2005.

E ch stu ent is encour ge to ccess n use the Web- M lcov tti L, Dell Port MG, P scutto C, et l. Prognostic ctors n

b se co p nion resources evelope or this ch pter. li e expect ncy in yelo yspl stic syn ro es cl ssif e ccor ing

Here you will f n ition l le rning tools to incre se to WHO criteri : b sis or clinic l ecision king, J Clin Oncol,

your un erst n ing o the concepts n clinic l pplic - 23(30):7594–7603, 2005.

tions o the ch pter. Mu i GJ, Bennett JM, Go sguen J, et l. Di gnosis n cl ssif c tion
o yelo yspl stic syn ro e: Intern tion l Working Group on

Morphology o Myelo yspl stic Syn ro e (IWGM-MDS) consen-

sus propos ls or the ef nition n enu er tion o yelobl sts n
BIBLIOGRAPHY ring si erobl sts, Haematologica, 93(11):1712–1717, 2008.

Ni er SD. Myelo yspl stic syn ro es, Blood, 111(10):4841–4851, 2008.

Arber DA, H sserji n RP. Recl ssi ying yelo yspl stic syn ro es: P ron E. Surveying the l n sc pe o MDS/MPH rese rch: overl p

wh t’s where in the new WHO n why, Hematology Am Soc ong the overl p syn ro es? Am Soc o Hematology Annual
Hematol Educ Program, 2015:294–298, 2015. Meeting Education Program, 349–354, 2015.

Bennett JM, Moloney WC, Greene MH, et l. Acute yeloi leuke i Schroe er MA, DeZern AE. Do so tic ut tions in e novo MDS

n other yelop thic isor ers ollowing tre t ent with lkyl t- pre ict or response to tre t ent? Hematology Am Soc Hematol

ing gents, Hematol Pathol, 1(2):99–104, 1987. Educ Program, 2015:317–328, 2015.

Borbényi Z, V rg G, Bérczi M, et l. F ctors in uencing leuke- Seo IS, Li CY. Myelo yspl stic syn ro e: i gnostic i plic tions o
ic tr ns or tion in yelo yspl stic syn ro e, Orv Hetil, cytoche ic l n i unocytoche ic l stu ies, Mayo Clin Proc,

131(23):1231–1236, 1239, 1240, 1990. 68(1):47–53, 1993.

DeZern AE. Nine ye rs without new FDA- pprove ther py or Sri h r K, Ross D , ibshir ni R, et l. Rel tionship o i erenti l gene
MDS: how c n we bre k through the i p sse? Hematology Am Soc expression prof les in CD34+ yelo yspl stic syn ro e rrow cells

Hematol Educ Program, 2015:308–316, 2015. to ise se subtype n progression, Blood, 114(23):4847–4858, 2009.

He ney ML, Gol e DW. Myelo yspl si , N Engl J Med, 340(21) urgeon ML. Myelo yspl stic syn ro es, Guthrie J, 61(4):149–159,

:1649–1660, 1999. 1992.